PPARA and metabolic dysfunction-associated steatohepatitis: The future discovery of anti-NASH (or anti-metabolic disease) PPAR agonists will unequivocally have fundamental benefits from the in-depth functional and structural investigation of PPARα/δ/γ-LBD–ligand molecular interactions.